COMPANY EVALUATION
Business models and capital allocation
Assess operating economics, cash generation, competitive positioning, capital requirements, dilution, and the quality of management decisions.
Independent evaluations of health care businesses, medical technologies, markets, and management strategy.
Selected engagements may include due diligence for private equity and venture capital investors, evaluation of emerging medical technologies, assessment of management and business models, and analysis of commercial opportunities and risks.
Ruffin Health combines clinical medicine, epidemiology, executive experience, and financial analysis to examine the strengths, weaknesses, and economic prospects of health care companies and technologies.
Assess operating economics, cash generation, competitive positioning, capital requirements, dilution, and the quality of management decisions.
Evaluate evidence of clinical utility, incidence and prevalence, test performance, addressable markets, adoption barriers, and economic incentives.
Identify technical, clinical, operational, and governance problems that could affect commercial success and long-term shareholder returns.
An engagement begins with a defined question and a clear scope. Conclusions may be favorable, unfavorable, or inconclusive. We distinguish documented facts from interpretation, identify material limitations, and disclose relevant conflicts.
Ruffin Health's longer-term research objective is to develop and validate a prospective investment evaluation framework. It is not presented as a proven forecasting system.
For selected research and advisory inquiries, write to info@ruffin.com.
Contact Ruffin Health